Background The signal transduction pathways of epidermal growth factor receptor and Ras
are both important in the growth of glioblastoma multiforme (GBM). We hypothesized that …

Background Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic
target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma …

1555 Background: Erlotinib HCL (Tarceva), an orally active, highly potent and selective
inhibitor of the epidermal growth factor receptor (HER1/EGFR), has documented clinical …

Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …

2005 Background: Single agent targeted therapy has been disappointing in GBM.
Combination therapy simultaneously targeting both EGFR and the MAP kinase pathway may …

Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is active in
glioblastoma. We evaluated erlotinib efficacy in patients with first-relapse glioblastoma and …

1558 Background: Erlotinib (Tarceva, OSI-774) is an orally available small molecule
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. We have initiated the first …

The purpose of this study was to define the maximum tolerated dose of erlotinib and
characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and …

We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase
inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the …

Purpose: To evaluate the toxicity and maximum tolerated dose (MTD) of erlotinib plus
radiation therapy (RT) in patients with glioblastoma multiforme (GBM) in a multicenter phase …